Evidence map›Paper›PMID 42449353›Full record

ArticleJournal of nanobiotechnology2026

Navitoclax-encapsulated dual pH-responsive copolymeric nanoparticles improves hepatocellular carcinoma treatment with induction of apoptosis and immune activation.

Jiahao Wang, Tianao Xie, Heng Jiang, Yukai Shan, Sarun Juengpanich, Shijie Li, Win Topatana, Yeling Liu, Hong Wan, Yeben Qian and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jiahao Wang *Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Tianao Xie *Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China.
Heng Jiang *Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Yukai Shan *Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China.
Sarun JuengpanichDepartment of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China.
Shijie LiDepartment of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China.
Win TopatanaDepartment of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China.
Yeling LiuDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, 100191, China.
Hong WanDepartment of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China. wanhong@ahmu.edu.cn.
Yeben QianDepartment of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China. qianyeben@hotmail.com.
Peng ChenDepartment of General Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China. efy101447@fy.ahmu.edu.cn.
Bo ChenDepartment of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China. chenbo@ahmu.edu.cn.

Funding

Health Research Program of Anhui AHWJ2023BAc20059the Anhui Provincial Natural Science Foundation 2208085MH240the National Natural Science Foundation of China 82500729the Scientific Research Project of Anhui Provincial Department of Education 2022AH051167
6 · The paper itself

Abstract

backgroundNavitoclax (ABT-263) exhibits strong cytotoxic effects against hepatocellular carcinoma cells in vitro; however, its therapeutic efficacy in vivo is limited by insufficient local drug accumulation and compensatory upregulation of the anti-apoptotic protein myeloid cell leukemia-1 during long-term treatment. In addition, effective immune activation in hepatocellular carcinoma remains challenging due to the immune-privileged hepatic microenvironment. This study aimed to overcome these limitations through a tumor-targeted nanotherapeutic strategy.

resultsDual pH-responsive copolymeric nanoparticles modified with folic acid and co-loaded with navitoclax and indocyanine green (FPN

conclusionsThis study demonstrates that FPN

Indexed as

Aniline CompoundsAntineoplastic AgentsApoptosisCarcinoma, HepatocellularLiver NeoplasmsNanoparticlesSulfonamidesAnimalsCell Line, TumorFolic AcidHumansHydrogen-Ion ConcentrationIndocyanine GreenMicePolymersReactive Oxygen SpeciesAniline CompoundsAntineoplastic AgentsFolic AcidIndocyanine GreennavitoclaxPolymersReactive Oxygen SpeciesSulfonamidesHepatocellular carcinomaImmunogenic cell deathNnavitoclaxReactive oxygen species

Identifiers

PMID42449353

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.